Skip to content
OPT1OPT1OPT1

Drawing based on the label description. No photo yet.

“Tofacitinib extended-release tablets: 11 mg tofacitinib: Yellow, cylindrical, extended-release film-coated tablets imprinted with "OPT1" in black color”

OPT1 pill

Pill with imprint OPT1 is yellow, capsule, 13 mm and has been identified as Tofacitinib 11 mg. It is used for rheumatoid arthritis. It is supplied by Exelan Pharmaceuticals,inc.

Tofacitinib 11 mg

Imprint
OPT1
Strength
11 mg
Used for
Rheumatoid arthritis
Color
Yellow
Shape
Capsule / oblong
Size
13 mm
Score
No score line
Form
Tablet, film coated, extended release
Manufacturer
Exelan Pharmaceuticals,inc
Drug class
Cancer medicine (kinase inhibitor)
NDC
76282-816, 76282-816-30, 76333-111, 76333-111-15

Source: the official drug label on DailyMed (US National Library of Medicine). Last checked .

Report a mistake

Please do not include personal health information. For questions about your medicine, ask a pharmacist.

All Tofacitinib pills and guides

What is Tofacitinib used for?

Tofacitinib is used for rheumatoid arthritis.

Medicine type
Cancer medicine (kinase inhibitor)
Official uses from the US prescribing label

Rheumatoid Arthritis

Tofacitinib extended-release tablets are indicated for the treatment of adult patients with moderately to severely active rheumatoid arthritis (RA), who have had an inadequate response or intolerance to one or more TNF blockers.

Limitations of Use

Use of tofacitinib extended-release tablets in combination with biologic disease-modifying antirheumatic drugs (DMARDs) or with potent immunosuppressants such as azathioprine and cyclosporine is not recommended.

Psoriatic Arthritis

Tofacitinib extended-release tablets are indicated for the treatment of adults with active PsA who have had an inadequate response or intolerance to one or more TNF blockers.

Limitations of Use

Use of tofacitinib extended-release tablets in combination with biologic DMARDs or with potent immunosuppressants such as azathioprine and cyclosporine is not recommended.

Ankylosing Spondylitis

Tofacitinib extended-release tablets are indicated for the treatment of adult patients with active ankylosing spondylitis (AS), who have had an inadequate response or intolerance to one or more TNF blockers.

Limitations of Use

Use of tofacitinib extended-release tablets in combination with biologic DMARDs or potent immunosuppressants such as azathioprine and cyclosporine is not recommended.

From the FDA-approved label on DailyMed (published Oct 05, 2026).

Doctors sometimes prescribe a medicine for other reasons too. If you are not sure what yours is for, ask your pharmacist.

Is this your pill? Check every detail

  • Your pill shows OPT1.
  • It is yellow, capsule, 13 mm.
  • Its score line and coating match the details on this page.
  • It came from a pharmacy package that names the same drug.

Ingredients

Active: Tofacitinib Citrate

Inactive: Fructose, Starch, Corn, Cellulose Acetate, Hydroxyethyl Cellulose, Unspecified, Hydroxypropyl Cellulose, Unspecified, Hypromellose 2910 (5 Mpa.s), Magnesium Stearate, Brown Iron Oxide, Polyvinyl Alcohol, Talc, Titanium Dioxide, Sodium Lauryl Sulfate, Ferric Oxide Yellow, Ferric Oxide Red, Propylene Glycol, Shellac, Ferrosoferric Oxide, Glyceryl Mono- and Dicaprylocaprate

Also distributed by

Orient Pharma Co., Ltd. Yunlin Plant

Pills that look similar but are different drugs

Same color and shape, different medicine. This is why the imprint matters.

Other Tofacitinib pills